| Literature DB >> 18154362 |
Sarah C Garrett1, Louis Hodgson, Andrew Rybin, Alexei Toutchkine, Klaus M Hahn, David S Lawrence, Anne R Bresnick.
Abstract
S100A4, a member of the S100 family of Ca2+-binding proteins, displays elevated expression in malignant human tumors compared with benign tumors, and increased expression correlates strongly with poor patient survival. S100A4 has a direct role in metastatic progression, likely due to the modulation of actomyosin cytoskeletal dynamics, which results in increased cellular motility. We developed a fluorescent biosensor (Mero-S100A4) that reports on the Ca2+-bound, activated form of S100A4. Direct attachment of a novel solvatochromatic reporter dye to S100A4 results in a sensor that, upon activation, undergoes a 3-fold enhancement in fluorescence, thus providing a sensitive assay for use in vitro and in vivo. In cells, localized activation of S100A4 at the cell periphery is observed during random migration and following stimulation with lysophosphatidic acid, a known activator of cell motility and proliferation. Additionally, a screen against a library of FDA-approved drugs with the biosensor identified an array of phenothiazines as inhibitors of myosin-II associated S100A4 function. These data demonstrate the utility of the new biosensor both for drug discovery and for probing the cellular dynamics controlled by the S100A4 metastasis factor.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18154362 PMCID: PMC3227476 DOI: 10.1021/bi7021624
Source DB: PubMed Journal: Biochemistry ISSN: 0006-2960 Impact factor: 3.162